Literature DB >> 31307996

Effect of Lipoprotein(a) on the Diagnosis of Familial Hypercholesterolemia: Does It Make a Difference in the Clinic?

Dick C Chan1, Jing Pang1, Amanda J Hooper1,2, Damon A Bell1,2,3, John R Burnett1,2,3, Gerald F Watts4,3.   

Abstract

BACKGROUND: Diagnostic tools for familial hypercholesterolemia (FH) rely on estimation of LDL cholesterol concentration. However, routine measurement or calculation of LDL cholesterol concentration using the Friedewald equation contains a cholesterol contribution from lipoprotein(a) [Lp(a)]. We investigated whether Lp(a) influences the phenotypic diagnosis of FH by commonly used clinical criteria.
METHODS: A cohort of 907 adult index patients attending a clinic were studied. The Dutch Lipid Clinic Network (DLCN) and Simon Broome (SB) diagnostic criteria were estimated before and after adjusting LDL cholesterol concentration for the cholesterol content (30%) of Lp(a). Diagnostic reclassification rates and area under the ROC (AUROC) curves in predicting an FH mutation were also compared.
RESULTS: Seventy-four patients defined by DLCN criteria (8.2%) and 207 patients defined by SB criteria (22.8%) were reclassified to "unlikely" FH after adjusting LDL cholesterol for Lp(a) cholesterol. The proportion of FH patients defined by DLCN (probable/definite) and SB (possible/definite) criteria decreased significantly in patients with increased Lp(a) (>0.5 g/L; n = 330) after Lp(a) cholesterol adjustment (P < 0.01). The overall reclassification rate was significantly higher in patients with Lp(a) concentration >1.0 g/L (P < 0.001). The AUROC curve for LDL cholesterol concentration ≥191 mg/dL (≥5.0 mmol/L), DLCN criteria, and SB criteria in predicting an FH mutation increased significantly after adjustment (P < 0.001). There was no significant difference in AUROC curve before and after Lp(a) cholesterol adjustment at an LDL cholesterol concentration ≥251 mg/dL (≥6.5 mmol/L).
CONCLUSIONS: Adjusting LDL cholesterol concentration for Lp(a) cholesterol improves the diagnostic accuracy of DLCN and SB criteria, especially with Lp(a) >1.0 g/L and LDL cholesterol <251 mg/dL (<6.5 mmol/L). Lp(a) should be measured in all patients suspected of having FH.
© 2019 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31307996     DOI: 10.1373/clinchem.2019.306738

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

Review 1.  Successful Genetic Screening and Creating Awareness of Familial Hypercholesterolemia and Other Heritable Dyslipidemias in the Netherlands.

Authors:  Linda C Zuurbier; Joep C Defesche; Albert Wiegman
Journal:  Genes (Basel)       Date:  2021-07-29       Impact factor: 4.096

Review 2.  Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care.

Authors:  Wann Jia Loh; Dick C Chan; Pedro Mata; Gerald F Watts
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.772

Review 3.  Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study.

Authors:  David Šuran; Helena Blažun Vošner; Jernej Završnik; Peter Kokol; Andreja Sinkovič; Vojko Kanič; Marko Kokol; Franjo Naji; Tadej Završnik
Journal:  Front Public Health       Date:  2022-07-05

Review 4.  Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care.

Authors:  Gerald F Watts; Samuel S Gidding; Pedro Mata; Jing Pang; David R Sullivan; Shizuya Yamashita; Frederick J Raal; Raul D Santos; Kausik K Ray
Journal:  Nat Rev Cardiol       Date:  2020-01-23       Impact factor: 32.419

5.  Elevated Lipoprotein(a) Level Influences Familial Hypercholesterolemia Diagnosis.

Authors:  Uliana V Chubykina; Marat V Ezhov; Olga I Afanasieva; Elena A Klesareva; Sergei N Pokrovsky
Journal:  Diseases       Date:  2022-01-18

Review 6.  Lp(a): a New Pathway to Target?

Authors:  Nick S Nurmohamed; Jordan M Kraaijenhof; Erik S G Stroes
Journal:  Curr Atheroscler Rep       Date:  2022-09-06       Impact factor: 5.967

7.  The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the Russian Federation: The FH-ESSE-RF Study.

Authors:  Alexey N Meshkov; Alexandra I Ershova; Anna V Kiseleva; Svetlana A Shalnova; Oxana M Drapkina; Sergey A Boytsov
Journal:  J Pers Med       Date:  2021-05-24

Review 8.  Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach.

Authors:  Maria Francesca Greco; Cesare R Sirtori; Alberto Corsini; Marat Ezhov; Tiziana Sampietro; Massimiliano Ruscica
Journal:  J Clin Med       Date:  2020-07-03       Impact factor: 4.964

9.  Familial Hypercholesterolaemia in the Malaysian Community: Prevalence, Under-Detection and Under-Treatment.

Authors:  Yung-An Chua; Aimi Zafira Razman; Anis Safura Ramli; Noor Alicezah Mohd Kasim; Hapizah Nawawi
Journal:  J Atheroscler Thromb       Date:  2021-01-15       Impact factor: 4.928

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.